The mechanisms underlying the pathogenicity of these antibodies in PTR include: (a) the induction of FcγRIIa-dependent platelet activation and enhanced phagocytosis by macrophages [17]; (b) the activation of complement through the deposition of C4b and C3b and the formation of the membrane-attack complex (MAC) [18]. The gene discussed is C3; the disease is pilomatrixoma.